Page 33 - Bio Developments News Today

The biotech startup Immune Bridge has bagged $12 million in a seed financing round to drive the development of natural killer (NK) cells that can be used in cell therapies for cancer.

Moderna has announced new mRNA vaccine development programs: with the Lyme disease candidate representing an expansion of the company's mRNA tech to target bacterial pathogens.

A Phase 1 trial found that a freeze-dried, temperature-stable experimental tuberculosis vaccine was safe, well-tolerated and elicited robust antigen-specific serum antibody and Th1-type cellular immune responses.

Aspect Biosystems and Novo Nordisk have announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics to replace or repair biological functions in the body: with the aim of creating a ‘new class of truly disease-modifying treatments’ for diabetes and obesity.

The clinical stage company announces that its potential treatment for relapsed or refractory multiple myeloma receives nod for speedier review by the FDA.

The U.S. biotech Alzamend Neuro has launched a phase 1/2a trial of a therapeutic vaccine for Alzheimer’s disease based on a patient’s immune dendritic cells.

Sensible Biotechnologies will partner with Ginkgo Bioworks to develop an in vivo microbial mRNA manufacturing platform – aiming to address a major bottleneck in mRNA manufacturing.

The company finalizes a deal to establish its first manufacturing facility in Africa, which will have the capacity to produce 500 million vaccine doses per year.

BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets: thus adding ADCs as an additional drug class in BioNTech’s oncology portfolio.

Swiss CDMO Lonza has increased capacity and capabilities at its Visp, Switzerland site, with the completion of a new line for cGMP clinical and commercial drug product manufacturing.